本文通过实验对比了 CD147-CAR-NK 与 CD147-CAR-T 疗法的毒性，发现前者安全性更优，为癌症治疗带来新希望。 嵌合抗原受体自然杀伤细胞（CAR-NK）疗法治疗实体瘤的毒性研究进展：安全性与潜力挖掘 癌症治疗一直是生命科学领域的重要研究方向，随着医学技术的 ...

When combined with CARs, the natural killer (NK) cells can also be trained to target specific cancers, with several unique features that give CAR-NK a potential advantage over CAR-T therapy.

For solid tumors and hematological malignancies, CAR-NK cell treatment is a novel kind of cancer immunotherapy. CAR-NK cells work by killing cancer cells in a CAR-dependent way. CAR-NK cells and ...

CAR-T and CAR-natural killer (NK). These cells are genetically modified, often using viral vectors, to express CARs on their surface, specifically engineered to recognize a certain antigen presented ...

The two phase 1 trials of the California biotech's lead CAR-NK candidates showed that the therapies were able to induce complete responses in two groups of patients with hard-to-treat, heavily pre ...

Chimeric antigen receptor (CAR) cell therapies are a rapidly developing potential therapeutic option for patients with cancer and autoimmune diseases. But what does CAR therapy look like and what are ...

"With this first patient dosing, we anticipate contributing to both the advancement of CAR-NK therapies and the expansion of this emerging treatment landscape." Preclinical efficacy data presented ...

YONGIN, South Korea, March 13, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 ...